Chronic myeloproliferative diseases.
de Lacerda JF, Oliveira SN, Ferro JM.
Handb Clin Neurol. 2014;120:1073-81. doi: 10.1016/B978-0-7020-4087-0.00072-3.
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S.
Cells. 2021 Dec 16;10(12):3551. doi: 10.3390/cells10123551.
Philadelphia chromosome-negative chronic myeloproliferative disease.
Thiele J.
Am J Clin Pathol. 2009 Aug;132(2):261-80. doi: 10.1309/AJCPR8GINMBDG9YG.
Myeloproliferative neoplasms: young patients, current data and future considerations.
Sobas M, Ianotto JC, Kiladjian JJ, Harrison C.
Ann Hematol. 2024 Sep;103(9):3287-3291. doi: 10.1007/s00277-024-05920-8. Epub 2024 Aug 7.
Angiogenesis in chronic myeloproliferative diseases.
Di Raimondo F, Palumbo GA, Molica S, Giustolisi R.
Acta Haematol. 2001;106(4):177-83. doi: 10.1159/000046614.
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
Tefferi A.
Mayo Clin Proc. 1998 Dec;73(12):1177-84. doi: 10.4065/73.12.1177.
[Chronic myeloproliferative syndromes].
de Ozalla CB, García Suárez J.
Rev Clin Esp. 1999 Apr;199 Suppl 1:28-36.
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM.
Leukemia. 2009 Oct;23(10):1708-15. doi: 10.1038/leu.2009.142. Epub 2009 Jul 30.
CMML: a biologically distinct myeloproliferative disease.
Cortes J.
Curr Hematol Rep. 2003 May;2(3):202-8.
Prefibrotic myelofibrosis: treatment algorithm 2018.
Finazzi G, Vannucchi AM, Barbui T.
Blood Cancer J. 2018 Nov 7;8(11):104. doi: 10.1038/s41408-018-0142-z.
